Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrizia Giannatempo

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
Biologics : Targets & Therapy|November 10, 2021
Biological Therapeutic Advances for the Treatment of Advanced Urothelial CancersMimma Rizzo, Patrizia Giannatempo, Camillo Porta
Future Oncology (London, England)|June 22, 2018
Nivolumab and its use in the second-line treatment of metastatic urothelial cancerDaniele Raggi, Andrea Necchi, Patrizia Giannatempo
Advances in Therapy|April 15, 2026
Empowering Patients: The Role of Shared Treatment Decision-Making in Advanced Bladder Cancer-A PodcastRavindran Kanesvaran, Patrizia Giannatempo, Alex Filicevas
Future Oncology (London, England)|April 7, 2022
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain <i>FGFR</i> genetic alterationsAndrea Franza, Marta Pirovano, Patrizia Giannatempo, et al.
Current Opinion in Urology|October 14, 2017
Immunotherapy for metastatic urothelial carcinoma: status quo and the futureAndrea Necchi, Michael Rink, Patrizia Giannatempo, et al.
Cancer Treatment and Research Communications|April 10, 2021
Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysisFausto Petrelli, Patrizia Giannatempo, Carmen Maccagnano, et al.
Expert Review of Anticancer Therapy|September 24, 2019
Erdafitinib for the treatment of urothelial cancerLaura Marandino, Daniele Raggi, Patrizia Giannatempo, et al.
Investigational New Drugs|February 4, 2017
Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertibAndrea Necchi, Giulia Pintarelli, Daniele Raggi, et al.
Oncology Research and Treatment|May 5, 2025
Management of Advanced Penile CancerRamona Stelmach, Patrizia Giannatempo, Nicola Nicolai, et al.
Expert Opinion on Pharmacotherapy|September 2, 2020
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomasCamillo Porta, Patrizia Giannatempo, Mimma Rizzo, et al.
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
Biologics : Targets & Therapy|November 10, 2021
Biological Therapeutic Advances for the Treatment of Advanced Urothelial CancersMimma Rizzo, Patrizia Giannatempo, Camillo Porta
Future Oncology (London, England)|June 22, 2018
Nivolumab and its use in the second-line treatment of metastatic urothelial cancerDaniele Raggi, Andrea Necchi, Patrizia Giannatempo
Advances in Therapy|April 15, 2026
Empowering Patients: The Role of Shared Treatment Decision-Making in Advanced Bladder Cancer-A PodcastRavindran Kanesvaran, Patrizia Giannatempo, Alex Filicevas
Future Oncology (London, England)|April 7, 2022
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain <i>FGFR</i> genetic alterationsAndrea Franza, Marta Pirovano, Patrizia Giannatempo, et al.
Current Opinion in Urology|October 14, 2017
Immunotherapy for metastatic urothelial carcinoma: status quo and the futureAndrea Necchi, Michael Rink, Patrizia Giannatempo, et al.
Cancer Treatment and Research Communications|April 10, 2021
Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysisFausto Petrelli, Patrizia Giannatempo, Carmen Maccagnano, et al.
Expert Review of Anticancer Therapy|September 24, 2019
Erdafitinib for the treatment of urothelial cancerLaura Marandino, Daniele Raggi, Patrizia Giannatempo, et al.
Investigational New Drugs|February 4, 2017
Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertibAndrea Necchi, Giulia Pintarelli, Daniele Raggi, et al.
Oncology Research and Treatment|May 5, 2025
Management of Advanced Penile CancerRamona Stelmach, Patrizia Giannatempo, Nicola Nicolai, et al.
Expert Opinion on Pharmacotherapy|September 2, 2020
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomasCamillo Porta, Patrizia Giannatempo, Mimma Rizzo, et al.
Pageof 14